Promising drug may shrink brain tumors in relapsed lymphoma
NCT ID NCT04548648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and works by targeting a specific protein in cancer cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Moffit Cancer Center
Tampa, Florida, 33612, United States
-
Wake Forest University,The Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157-1096, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can lifestyle choices after a stroke extend life and prevent a second one?
- What happens years after CAR-T therapy? a study aims to find out
- Engineered immune cells take on tough lymphomas
- Immune cells take on brain cancer in first human test
- Brain cancer breakthrough? CAR t cells injected directly into fluid around brain in new trial
- Experimental pill plus chemo takes aim at Hard-to-Treat brain lymphoma